Prognostic value of red blood cell distribution width in tumors

doi:10.3760/cma.j.issn.1673-422X.2019.08.008

Abstract

Abstract: Red blood cell distribution width (RDW) is a conventional digital index for diagnosis of anemia, and recent studies have found its new clinical significance: high RDW is closely related to prognosis and diagnosis of both solid tumors and hematological tumors in addition to acute and chronic kidney disease, chronic obstructive pulmonary disease and cardiovascular disease. RDW, which is cheap and easily acquired, may offer a new direction for clinical diagnosis and prognosis of tumor though the relevant mechanism is unclear.

Key words: Neoplasms, Prognosis, Red blood cell distribution width

Ye Jiannan, Sun Chao, Li Jianyong, Zhou Xin. Prognostic value of red blood cell distribution width in tumors[J]. Journal of International Oncology, 2019, 46(8): 485-488.

References

［1］ Arbel Y, Weitzman D, Raz R, et al. Red blood cell distribution width and the risk of cardiovascular morbidity and all-cause mortality. A population-based study［J］. Thromb Haemost, 2014, 111(2): 300-307. DOI: 10.1160/TH13-07-0567. ［2］ Solak Y, Yilmaz MI, Saglam M, et al. Red cell distribution width is independently related to endothelial dysfunction in patients with chronic kidney disease［J］. Am J Med Sci, 2014, 347(2): 118-124. DOI: 10.1097/MAJ.0b013e3182996a96. ［3］ Balta S, Aydogan M, Demirkol S, et al. Red cell distribution width: a novel and simple predictor of mortality in chronic obstructive pulmonary disease［J］. COPD, 2014, 11(4): 475-476. DOI: 10.3109/15412555.2013.813449. ［4］ Patel HH, Patel H, Higgins JM. Modulation of red blood cell population dynamics is a fundamental homeostatic response to disease［J］. Am J Hematol, 2015, 90(5): 422-428. DOI: 10.1002/ajh.23982. ［5］ Chrobk L, Zk P, Podzimek K, et al. Red cell distribution width (RDW) as a marker of disease activity in patients with hairy cell leukemia［J］. Acta Medica (Hradec Kralove), 1998, 41(1): 23-26. ［6］ Iriyama N, Hatta Y, Kobayashi S, et al. Higher red blood cell distribution width is an adverse prognostic factor in chronic-phase chronic myeloid leukemia patients treated with tyrosine kinase inhibitors［J］. Anticancer Res, 2015, 35(10): 5473-5478. ［7］ Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes［J］. N Engl J Med, 2014, 371(26): 2488-2498. DOI: 10.1056/NEJMoa1408617. ［8］ Podhorecka M, Halicka D, Szymczyk A, et al. Assessment of red blood cell distribution width as a prognostic marker in chronic lymphocytic leukemia［J］. Oncotarget, 2016, 7(22): 32846-32853. DOI: 10.18632/oncotarget.9055. ［9］ Bulycheva E, Rauner M, Medyouf H, et al. Myelodysplasia is in the niche: novel concepts and emerging therapies［J］. Leukemia, 2015, 29(2): 259-268. DOI: 10.1038/leu.2014.325. ［10］ Muto Y, Nishiyama M, Nita A, et al. Essential role of FBXL5-mediated cellular iron homeostasis in maintenance of hematopoietic stem cells［J］. Nat Commun, 2017, 8: 16114. DOI: 10.1038/ncomms16114. ［11］ Raess PW, van de Geijn GJ, Njo TL, et al. Automated screening for myelodysplastic syndromes through analysis of complete blood count and cell population data parameters［J］. Am J Hematol, 2014, 89(4): 369-374. DOI: 10.1002/ajh.23643. ［12］ Baba Y, Saito B, Shimada S, et al. Association of red cell distribution width with clinical outcomes in myelodysplastic syndrome［J］. Leuk Res, 2018, 67: 56-59. DOI: 10.1016/j.leukres.2018.02.004. ［13］ Periˇsa V, Zibar L, Sinˇci＇c-Petriˇcevi＇c J, et al. Red blood cell distribution width as a simple negative prognostic factor in patients with diffuse large B-cell lymphoma: a retrospective study［J］. Croat Med J, 2015, 56(4): 334-343. DOI: 10.3325/cmj.2015.56.334. ［14］ Zhou S, Fang F, Chen H, et al. Prognostic significance of the red blood cell distribution width in diffuse large B-cell lymphoma patients［J］. Oncotarget, 2017, 8(25): 40724-40731. DOI: 10.18632/oncotarget.16560. ［15］ Luo H, Quan X, Song XY, et al. Red blood cell distribution width as a predictor of survival in nasal-type, extranodal natural killer/T-cell lymphoma［J］. Oncotarget, 2017, 8(54): 92522-92535. DOI: 10.18632/oncotarget.21439. ［16］ Lee H, Kong SY, Sohn JY, et al. Elevated red blood cell distribution width as a simple prognostic factor in patients with symptomatic multiple myeloma.［J］. Biomed Res Int, 2014, 2014: 145619. DOI: 10.1155/2014/145619. ［17］ Meng S, Ma Z, Lu C, et al. Prognostic value of elevated red blood cell distribution width in Chinese patients with multiple myeloma［J］. Ann Clin Lab Sci, 2017, 47(3): 282-290. ［18］ Wang J, Xie X, Cheng F, et al. Evaluation of pretreatment red cell distribution width in patients with multiple myeloma［J］. Cancer Biomarker, 2017, 20(3): 267-272. DOI: 10.3233/CBM-170032. ［19］ Zhou D, Xu P, Peng M, et al. Pre-treatment red blood cell distribution width provides prognostic information in multiple myeloma［J］. Clin Chim Acta, 2018, 481: 34-41. DOI: 10.1016/j.cca.2018.02.009. ［20］ Zhang F, Chen Z, Wang P, et al. Combination of platelet count and mean platelet volume (COP-MPV) predicts postoperative prognosis in both resectable early and advanced stage esophageal squamous cell cancer patients［J］. Tumour Biol, 2016, 37(7): 9323-9331. DOI: 10.1007/s13277-015-4774-3. ［21］ Hirahara N, Matsubara T, Kawahara D, et al. Prognostic value of hematological parameters in patients undergoing esophagectomy for esophageal squamous cell carcinoma［J］. Int J Clin Oncol, 2016, 21(5): 909-919. DOI: 10.1007/s10147-016-0986-9. ［22］ Sun P, Zhang F, Cheng C, et al. The ratio of hemoglobin to red cell distribution width as a novel prognostic parameter in esophageal squamous cell carcinoma: a retrospective study from southern China［J］. Oncotarget, 2016, 7(27): 42650-42660. DOI: 10.18632/oncotarget.9516. ［23］ Xie D, Marks R, Zhang M, et al. Nomograms predict overall survival for patients with small-cell lung cancer incorporating pretreatment peripheral blood markers［J］. J Thorac Oncol, 2015, 10(8): 1213-1220. DOI: 10.1097/JTO.0000000000000585. ［24］ Warwick R, Mediratta N, Shackcloth M, et al. Preoperative red cell distribution width in patients undergoing pulmonary resections for non-small-cell lung cancer［J］. Eur J Cardiothorac Surg, 2014, 45(1): 108-113. DOI: 10.1093/ejcts/ezt275. ［25］ Wang FM, Xu G, Zhang Y, et al. Red cell distribution width is associated with presence, stage, and grade in patients with renal cell carcinoma.［J］. Dis Markers, 2014, 2014: 860419. DOI: 10.1155/2014/860419. ［26］ Huang DP, Ma RM, Xiang YQ. Utility of red cell distribution width as a prognostic factor in young breast cancer patients［J］. Medicine (Baltimore), 2016, 95(17): e3430. DOI: 10.1097/MD.0000000000003430. ［27］ Wang C, Civan J, Lai Y, et al. Racial disparity in breast cancer survival: the impact of pre-treatment hematologic variables［J］. Cancer Causes Control, 2015, 26(1): 45-56. DOI: 10.1007/s10552-014-0481-4. ［28］ Seretis C, Seretis F, Lagoudianakis E, et al. Is red cell distribution width a novel biomarker of breast cancer activity? Data from a pilot study［J］. J Clin Med Res, 2013, 5(2): 121-126. DOI: 10.4021/jocmr1214w. ［29］ Lippi G, Targher G, Montagnana M, et al. Relation between red blood cell distribution width and inflammatory biomarkers in a large cohort of unselected outpatients［J］. Arch Pathol Lab Med, 2009, 133(4): 628-632. DOI: 10.1043/1543-2165-133.4.628. ［30］ Wu W, Ma D, Wang P, et al. Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells［J］. FEBS J, 2016, 283(5): 834-849. DOI: 10.1111/febs.13633.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou. Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer [J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Qian Xiaotao, Shi Ziyi, Hu Ge, Wu Xiaowei. Efficacy of consolidation chemotherapy after radical radiotherapy and chemotherapy for stage Ⅲ-ⅣA esophageal squamous cell carcinoma： a real-world clinical study [J]. Journal of International Oncology, 2024, 51(6): 326-331.
[3]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun. Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer [J]. Journal of International Oncology, 2024, 51(6): 332-337.
[4]	Yuan Jian, Huang Yanhua. Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer [J]. Journal of International Oncology, 2024, 51(6): 338-343.
[5]	Chen Hongjian, Zhang Suqing. Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients [J]. Journal of International Oncology, 2024, 51(6): 344-349.
[6]	Guo Zehao, Zhang Junwang. Role of PFDN and its subunits in tumorigenesis and tumor development [J]. Journal of International Oncology, 2024, 51(6): 350-353.
[7]	Zhang Baihong, Yue Hongyun. Advances in anti-tumor drugs with new mechanisms of action [J]. Journal of International Oncology, 2024, 51(6): 354-358.
[8]	Xu Fenglin, Wu Gang. Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma [J]. Journal of International Oncology, 2024, 51(6): 359-363.
[9]	Wang Ying, Liu Nan, Guo Bing. Advances of antibody-drug conjugate in the therapy of metastatic breast cancer [J]. Journal of International Oncology, 2024, 51(6): 364-369.
[10]	Zhang Rui, Chu Yanliu. Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota [J]. Journal of International Oncology, 2024, 51(6): 370-375.
[11]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu. Research progress on intestinal flora and non-surgical treatment of the colorectal cancer [J]. Journal of International Oncology, 2024, 51(6): 376-381.
[12]	Fan Zhipeng, Yu Jing, Hu Jing, Liao Zhengkai, Xu Yu, Ouyang Wen, Xie Conghua. Predictive value of changes in inflammatory markers for prognosis in patients with advanced non-small cell lung cancer treated with the first-line immunotherapy plus chemotherapy [J]. Journal of International Oncology, 2024, 51(5): 257-266.
[13]	Liu Jing, Liu Qin, Huang Mei. Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm [J]. Journal of International Oncology, 2024, 51(5): 267-273.
[14]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin. Study on the clinical relationship between inflammatory burden index and gastric cancer [J]. Journal of International Oncology, 2024, 51(5): 274-279.
[15]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao. Effect of cancer nodules on liver metastases after radical resection of colorectal cancer [J]. Journal of International Oncology, 2024, 51(5): 280-285.